Theravance, Inc. (NASDAQ:THRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Recs

0
Player Avatar jmacn22 (68.59) Submitted: 2/5/2009 12:42:52 PM : Underperform Start Price: $16.26 THRX Score: +23.15

Should underperform

Featured Broker Partners


Advertisement